Efficacy of topically administered rho-kinase inhibitor AR-12286 in patients with exfoliation syndrome and ocular hypertension or glaucoma

Alon Skaat, Jessica V. Jasien, Robert Ritch

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: To evaluate the efficacy of rho-associated protein kinase inhibitor, AR-12286 topical solution, for its effect in eyes with exfoliation syndrome (XFS) and ocular hypertension (OHT) or exfoliative glaucoma (XFG) and examine any lasting effect on intraocular pressure (IOP) after discontinuation. Methods: Prospective, double-masked, randomized, interventional study. Patients with XFS and OHT or XFG were enrolled. The study eyes were treated once daily with AR-12286, randomized to 0.5% or 0.7% for 24 weeks. Visits included baseline, 1, 4, and 12 weeks after drug initiation; at 12 weeks AR-12286 was discontinued for 1 week and was resumed at week 13. At the week 24 visit, AR-12286 was discontinued, and a final reexamination was performed at week 25. Results: Ten patients were treated. Mean baseline IOP was 25±2.4mm Hg, mean IOP was reduced to 19.1±2.3mm Hg at 1 week (P<0.001), 17.5±3.6mm Hg at 4 weeks (P<0.001), and 17.4±3.6mm Hg at 12 weeks (P<0.001), yielding an average IOP reduction of 23.6%, 30%, and 30.4%, respectively. At the week 13 visit, 1 week after the drug was discontinued, mean IOP increased to 21.6±5.4mm Hg (P=0.06 compared with baseline visit). At week 24, the mean IOP was 21.8±7.8mm Hg (P=0.2, and AR-12286 was discontinued). At week 25, the mean IOP was 21.3±5.3mm Hg (P=0.06). Conclusions: AR-12286 was well tolerated and provided statistically significant reduction in IOP in patients with XFS and OHT or XFG. This drug may represent an additional therapeutic paradigm for the treatment of XFG.

Original languageEnglish
Pages (from-to)e807-e814
JournalJournal of Glaucoma
Volume25
Issue number9
DOIs
StatePublished - 2016

Keywords

  • Exfoliative glaucoma
  • Intraocular pressure
  • Ocular hypertension
  • Protein kinase inhibitor

Fingerprint

Dive into the research topics of 'Efficacy of topically administered rho-kinase inhibitor AR-12286 in patients with exfoliation syndrome and ocular hypertension or glaucoma'. Together they form a unique fingerprint.

Cite this